“…The risk of bias for the nonrandomized trials ranged from 0–4 stars according to the Newcastle‐Ottawa Scale, which indicates a moderate to high risk of bias 42 , 45 , 48 , 49 . The combination LE used was SMOFlipid in 6 studies, 46 , 49 ‐ 53 ClinOleic/Omegaven 1:1 in 2 studies, 45 , 48 and Lipoplus in 2 studies 47 , 51 (1 study used 2 combination LEs). Populations included premature infants, 50 ‐ 53 infants with short bowel syndrome (SBS), 45 , 48 infants undergoing heart surgery, 47 children receiving long‐term PN, 46 and children who developed PNALD 49 .…”